Cempra, Inc. , a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of...
Cempra has announced the publication of positive results from its pivotal Phase III clinical trial of Solitaire (solithromycin oral capsules)...
Cempra, Inc. has announced positive topline results from a global, pivotal Phase III clinical trial of solithromycin oral capsules (Solitaire-Oral)...
Cempra has received a Complete Response Letter (CRL) from the FDA relating to the company�s new drug applications (NDAs) for...
Cempra has announced the completion of its rolling submission of the New Drug Applications (NDA) for Solitaire (solithromycin) to the...
Cempra has announced that the majority of the U.S. FDA Antimicrobial Drugs Advisory Committee (AMDAC) voted (7-6) that efficacy results...
Cempra Inc. announced that data will be presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), in...
Cempra, Inc.has announced that the European Medicines Agency (EMA) has validated the company's marketing authorization application (MAA) seeking approval of...
Cempra has analyzed the data from the initial patient cohort of 262 patients in SOLITAIRE-U, a phase III study evaluating...
Background: The safety and efficacy of doravirine were compared with that of efavirenz as initial treatment of adults living with HIV-1 infection.